{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-036682","form_type":"8-K","ticker":null,"cik":"0001444307","company_name":"ONCOSEC MEDICAL Inc","filed_at":"2022-12-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.684912+00:00","generated_at":"2026-06-20T22:23:42.627958+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"OncoSec receives Nasdaq delisting notice for negative equity of $(984,449)","bullets":["Stockholders' equity was $(984,449) as of Oct 31, 2022, below Nasdaq's $2.5M minimum.","Company has until Feb 10, 2023 to submit a compliance plan; if accepted, up to 180 days to regain compliance.","Failure to regain compliance could lead to delisting, reduced liquidity, and impaired financing.","OncoSec is evaluating options and intends to submit a plan to Nasdaq."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-036682","json":"https://secwatch.observer/filing/0001493152-22-036682.json","markdown":"https://secwatch.observer/filing/0001493152-22-036682.md","text":"https://secwatch.observer/filing/0001493152-22-036682.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1444307/000149315222036682/0001493152-22-036682-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1444307/000149315222036682/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T22:23:42.627958+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aa7649c8086470a4ee861a6fd6f3ca5b2c7112f5","claim":"ONCOSEC MEDICAL Inc received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"December 27, 2022, OncoSec Medical Incorporated (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on Nasdaq to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. The Company reported stockholders’ equity of $(984,449) in its quarterly report on Form 10-Q for the period ended October 31, 2022, and, as a result, does not currently satisfy Listing Rule 5550(b)(1). The Notice has no immediate impact on the listing of the","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1444307/000149315222036682/0001493152-22-036682-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}